1. Home
  2. WINT vs RIME Comparison

WINT vs RIME Comparison

Compare WINT & RIME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WINT
  • RIME
  • Stock Information
  • Founded
  • WINT 1992
  • RIME 1982
  • Country
  • WINT United States
  • RIME United States
  • Employees
  • WINT N/A
  • RIME N/A
  • Industry
  • WINT Biotechnology: Biological Products (No Diagnostic Substances)
  • RIME
  • Sector
  • WINT Health Care
  • RIME
  • Exchange
  • WINT Nasdaq
  • RIME NYSE
  • Market Cap
  • WINT 1.5M
  • RIME 1.4M
  • IPO Year
  • WINT 1995
  • RIME 1994
  • Fundamental
  • Price
  • WINT $1.20
  • RIME $1.95
  • Analyst Decision
  • WINT Hold
  • RIME
  • Analyst Count
  • WINT 1
  • RIME 0
  • Target Price
  • WINT $350.00
  • RIME N/A
  • AVG Volume (30 Days)
  • WINT 7.7M
  • RIME 183.0K
  • Earning Date
  • WINT 04-15-2025
  • RIME 05-19-2025
  • Dividend Yield
  • WINT N/A
  • RIME N/A
  • EPS Growth
  • WINT N/A
  • RIME N/A
  • EPS
  • WINT N/A
  • RIME N/A
  • Revenue
  • WINT N/A
  • RIME $32,479,657.00
  • Revenue This Year
  • WINT N/A
  • RIME N/A
  • Revenue Next Year
  • WINT N/A
  • RIME N/A
  • P/E Ratio
  • WINT N/A
  • RIME N/A
  • Revenue Growth
  • WINT N/A
  • RIME 11.81
  • 52 Week Low
  • WINT $1.10
  • RIME $1.71
  • 52 Week High
  • WINT $737.50
  • RIME $394.00
  • Technical
  • Relative Strength Index (RSI)
  • WINT 27.23
  • RIME N/A
  • Support Level
  • WINT $1.22
  • RIME N/A
  • Resistance Level
  • WINT $2.17
  • RIME N/A
  • Average True Range (ATR)
  • WINT 0.32
  • RIME 0.00
  • MACD
  • WINT 0.20
  • RIME 0.00
  • Stochastic Oscillator
  • WINT 3.54
  • RIME 0.00

About WINT Windtree Therapeutics Inc.

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

About RIME ALGORHYTHM HOLDINGS INC

Algorhythm Holdings Inc is a holding company with two primary investments. It operates through its subsidiaries, one of which is an emerging leader in the AI-enabled global logistics industry. The other subsidiary is engaged in consumer karaoke products, Which designs and distributes the industry's widest assortment of at-home and in-car karaoke entertainment products.

Share on Social Networks: